Company intelligence / Profile preview

BioSensics

Newton, Massachusetts, United Statesbiosensics.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioSensics’ wearable sensors and digital platforms are validated in over a hundred clinical studies/trials across more than thirty countries. Their technologies are used as primary or secondary endpoints in multiple global clinical trials for neurological and rare disorders. The company has received significant NIH support to develop novel digital biomarkers, including recent grants to advance speech-based cognitive assessment tools.

Therapeutic areas: Neurology
Modalities: Device (wearable sensor)Digital biomarker platformNon-pharmacological therapy (digital monitoring/assessment)
Industry: Physiological Monitoring

Partnerships

Collaborations with Baylor College of Medicine and other academic institutionspartnerships with pharmaceutical companies for clinical trial technologies

Beyond the preview

Go deeper on BioSensics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSensics.

Explore the full profile